Summary
Across 107 trials (101,751 adults), multi-strain probiotics modestly lowered respiratory infection incidence (risk ratio 0.90, 95% confidence interval 0.82 to 0.98, moderate certainty), as did Bifidobacterium animalis (risk ratio 0.79) and catechin. The same analysis found high-dose vitamin D the most effective for COVID-19 or influenza (risk ratio 0.66).
Key points
- Compared with placebo, catechin (risk ratio 0.79), Bifidobacterium animalis (0.79) and multi-strain probiotics (0.90) were the most effective at lowering respiratory infection incidence.
- High-dose vitamin D was linked to fewer cases of COVID-19 or influenza (risk ratio 0.66, moderate certainty).
- Catechin and multi-strain probiotics shortened symptoms by about 2.6 and 1.0 days per infection.
- None of the supplements raised the risk of adverse events compared with placebo.
- Design: network meta-analysis of 107 randomized trials in 101,751 adults, searched to February 2025; few trials compared supplements head to head.
- Funding: Ningbo Top Medical and Health Research Program and the Zhejiang Provincial Disease Prevention and Control Science and Technology Plan.
